 |
|
|
|
|
New Lymphoma Drug Shows Promise
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 Kamen was impressed with the drug's apparent potency. While rituximab, another antibody therapeutic for NHL, is typically dosed at 375,000 micrograms per square meter per day, the authors of the current study saw effects at levels of 30 micrograms. "That just speaks to the biology and pharmacology here," he said.
As the current trial continues, additional trials, such as a phase 2 study of the drug's effect against acute lymphoblastic leukemia, a particularly aggressive disease, have been initiated, said Baeuerle. Preliminary data are expected at the American Society of Hematology annual meeting in December.
More information
Text Continues Below
For more on non-Hodgkin lymphoma, visit the National Cancer Institute.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 8/14/2008
|
|
SOURCES: Patrick Baeuerle, Ph.D., senior vice president and chief scientific officer, Micromet AG, Munich, Germany; Barton Kamen, M.D., Ph.D., chief medical officer, The Leukemia & Lymphoma Society, White Plains, N.Y.; Thomas Kipps, M.D., Ph.D., deputy director, research operations, Moores UCSD Cancer Center, La Jolla, Calif.; Aug. 15, 2008, Science
|
.gif)
